DPP-4 inhibitors, heart failure and type 2 diabetes: all eyes on safety

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Heart failure (HF) and diabetes mellitus (DM) are strongly associated, increasing morbidity and mortality.
• Diabetic cardiomyopathy involves neurohormonal disturbances and structural/functional cardiac changes.
• Poor glycemic control (HbA1c) may elevate HF risk, but evidence requires further clarification.

Purpose of the Study:

• To critically evaluate the evidence linking dipeptidyl-peptidase-4 (DPP-4) inhibitors to HF risk in type 2 diabetes (T2D) patients.
• To assess whether increased HF hospitalization risk observed with DPP-4 inhibitors is a class effect.
• To discuss DPP-4 inhibitor combination therapy in light of recent cardiovascular outcome trials.

Main Methods:

• Review of epidemiological data and randomized controlled trials (RCTs) on anti-hyperglycemic therapies.
• Analysis of specific trials such as SAVOR-TIMI 53 and TECOS concerning DPP-4 inhibitors and HF.
• Consideration of recent findings from ESC Congress and the EMPA-REG trial.

Main Results:

• Some glucose-lowering drugs, including DPP-4 inhibitors, have been linked to increased HF hospitalization risk.
• The SAVOR-TIMI 53 trial raised safety concerns regarding DPP-4 inhibitors and HF.
• The TECOS study and its sub-analyses indicate sitagliptin (a DPP-4 inhibitor) is not associated with increased HF risk, suggesting it's not a class effect.

Conclusions:

• Increased HF hospitalization risk does not appear to be a class effect of all DPP-4 inhibitors.
• Further research and careful patient selection are necessary when considering DPP-4 inhibitors in T2D patients with HF risk factors.
• The role of DPP-4 inhibitors in combination therapy requires ongoing evaluation.